Anavex Comments on President Obama’s Signing of National Alzheimer’s Project Act into Law

Hoboken, NJ — January 18, 2011 — Anavex Life Sciences Corp. (“Anavex”, AVXL.OB) today commented on President Obama’s signing of the National Alzheimer’s Project Act (NAPA) into law.  The passage of this landmark legislation lays the foundation for the first coordinated national plan to overcome Alzheimer’s disease. “NAPAis the largest legislative victory in many years…

Alzheimer’s Weekly Names ANAVEX 2-73 the Number One Most Promising Trial Drug in Alzheimer’s Disease and Anavex’s Phase I Clinical Program as “Trial of the Year”

Hoboken, NJ — January 6, 2011 — Anavex Life Sciences Corp. (“Anavex”, AVXL.OB) announced today that ANAVEX 2-73 has been named 2010’s “most promising trial drug” by the editorial staff at Alzheimer’s Weekly.  The publication selected the ANAVEX 2-73 trial from a field of over 100 trials that treat dementias such as Alzheimer’s and following…